Gill Inderbir S, Remer Erick M, Hasan Waleed A, Strzempkowski Brenda, Spaliviero Massimiliano, Steinberg Andrew P, Kaouk Jihad H, Desai Mihir M, Novick Andrew C
Section of Laparoscopic and Minimally Invasive Surgery, Glickman Urological Institute and Department of Radiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
J Urol. 2005 Jun;173(6):1903-7. doi: 10.1097/01.ju.0000158154.28845.c9.
We report intermediate term oncological followup data on 56 patients undergoing laparoscopic renal cryoablation, of whom each completed a 3-year followup.
Since September 1997, 56 patients undergoing laparoscopic renal cryoablation have completed a followup of 3 years each. The postoperative followup protocol comprised serial magnetic resonance imaging (MRI) at 1 day, months 1, 3, 6, 12, 18 and 24, and yearly thereafter for 5 years. Computerized tomography guided needle biopsy of the cryolesion was performed 6 months postoperatively and repeated if MRI findings were abnormal. Followup data were obtained prospectively.
For a mean renal tumor size of 2.3 cm mean intraoperative size of the created cryolesion was 3.6 cm. Sequential mean cryolesion size on MRI on postoperative 1 day, and at 3 and 6 months, and 1, 2 and 3 years was 3.7, 2.8, 2.3, 1.7, 1.2 and 0.9 cm, representing a 26%, 39%, 56%, 69% and 75% percent reduction in cryolesion size at 3 and 6 months, and 1, 2 and 3 years, respectively. At 3 years 17 cryolesions (38%) had completely disappeared on MRI. Postoperative needle biopsy identified locally persistent/recurrent renal tumor in 2 patients. In the 51 patients undergoing cryotherapy for a unilateral, sporadic renal tumor 3-year cancer specific survival was 98%. There was no open conversion, kidney loss, urinary fistula, dialysis requirement, or perirenal or port site recurrence in any patients.
Three-year outcomes following renal cryoablation are encouraging. Longer term (5-year) data are necessary to determine the proper place of renal cryotherapy among minimally invasive, nephron sparing options.
我们报告了56例行腹腔镜肾冷冻消融术患者的中期肿瘤学随访数据,所有患者均完成了3年随访。
自1997年9月起,56例行腹腔镜肾冷冻消融术的患者均完成了3年随访。术后随访方案包括术后1天、1、3、6、12、18和24个月进行系列磁共振成像(MRI)检查,此后每年检查1次,共5年。术后6个月进行计算机断层扫描引导下的冷冻病灶穿刺活检,若MRI检查结果异常则重复进行。随访数据为前瞻性获取。
肾肿瘤平均大小为2.3 cm,术中所形成的冷冻病灶平均大小为3.6 cm。术后1天、3个月、6个月以及1、2、3年时MRI上冷冻病灶的连续平均大小分别为3.7、2.8、2.3、1.7、1.2和0.9 cm,分别代表在3个月、6个月以及1、2、3年时冷冻病灶大小分别减少了26%、39%、56%、69%和75%。3年时,17个冷冻病灶(38%)在MRI上完全消失。术后穿刺活检发现2例患者存在局部持续性/复发性肾肿瘤。在51例行冷冻治疗的单侧散发性肾肿瘤患者中,3年癌症特异性生存率为98%。所有患者均未出现开放手术转换、肾丢失、尿瘘、透析需求或肾周或穿刺部位复发。
肾冷冻消融术后3年的结果令人鼓舞。需要更长期(5年)的数据来确定肾冷冻治疗在微创、保留肾单位治疗方法中的合适地位。